Circulating branched chain amino acid (BCAA) levels reflect metabolic health and dietary intake. However, associations with breast cancer are unclear. We evaluated circulating BCAA levels and breast cancer risk within the Nurses' Health Study (NHS) and NHSII (1,997 cases, 1,997 matched controls). 592 NHS women donated two blood samples 10 years apart. We estimate odds ratios (OR) and 95% confidence intervals (CI) of breast cancer risk in multivariable logistic regression models. We conducted an external validation with secondary analyses in the Women's Health Study (WHS; 1,297 cases). Among NHSII participants (predominantly premenopausal at blood collection), elevated circulating BCAA levels were associated with lower breast cancer risk (e.g., isoleucine highest vs. lowest quartile, multivariable OR(95% CI)=0.86(0.65-1.13), p-trend=0.20), with significant linear trends among fasting samples (e.g., isoleucine OR(95% CI)=0.74(0.53-1.05), p-trend=0.05). In contrast, among postmenopausal women, proximate measures (<10y from blood draw) were associated with increased breast cancer risk (e.g., isoleucine OR(95% CI)=1.63(1.12-2.39), p-trend=0.01), with stronger associations among fasting samples (OR(95% CI)=1.73(1.15-2.61), p-trend=0.01). Distant measures (10-20y since blood draw) were not associated with risk. In the WHS, a positive association was observed for distant measures of leucine among postmenopausal women: OR(95% CI)=1.31(0.97-1.75), p-trend=0.05. Although elevated circulating BCAA levels were associated with lower breast cancer risk among premenopausal NHSII women and higher risk of postmenopausal breast cancer in NHS (<10y from blood draw), independent of established risk factors, including adiposity, results were not validated in WHS. Additional studies are needed to understand the complex relationship between BCAAs, menopausal status, and risk of breast cancer.